Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Taletrectinib
Sponsor: Megan Kruse, MD
Collaborators: AnHeart Therapeutics Inc.